Clinical Trials List
2022-01-01 - 2026-03-31
Phase II
Recruiting4
Terminated2
ICD-10C00.0
Malignant neoplasm of external upper lip
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9140.0
Malignant neoplasm of upper lip, vermilion border
-
Trial Applicant
TaiRx, Inc.
-
Sponsor
-
Trial scale
Taiwan Multiple Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Ming-Chih Ho Division of General Surgery
- 施怡倫 Division of Radiology
- JA-DER LIANG Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yan-Shen Shan Division of General Surgery
- 邱彥程 Digestive System Department
- 趙盈瑞 Division of General Surgery
- Yih-Jyh Lin 未分科
- Pin-Nan Cheng Digestive System Department
- 簡世杰 Digestive System Department
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- I-Cheng Lee Digestive System Department
- San-Chi Chen Division of Hematology & Oncology
- 吳啟榮 Digestive System Department
- Rheun-Chuan Lee Division of Radiology
- 齊振達 Digestive System Department
- Yi-Ping Hung Division of Hematology & Oncology
- Chien-An Liu Division of Radiology
- 齊振達 Digestive System Department
- Pei-Chang Lee Digestive System Department
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 宋睿祥 Division of General Surgery
- 吳宗翰 Division of Hematology & Oncology
- HANG HUONG LING Division of Hematology & Oncology
- 吳鋒 Division of Hematology & Oncology
- 陳義展 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Ming-Chih Ho Division of General Surgery
- JA-DER LIANG Division of General Internal Medicine
- 施怡倫 Division of Radiology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
106 participants
-
Global
106 participants
